Press Release
Video What is ProDUBLIN Optimization, April 28, 2021 /PRNewswire/ – Medtronic plc (NYSE: MDT), a global leader in medical technology, today released results from an interim analysis of the first 171 patients (including 71) treated in the OPTIMIZE PRO clinical study. A prospective, multicenter, post-marketing study evaluating procedural outcomes (including pacemaker rates) in relation to procedure-related techniques and postoperative TAVR care pathways Using the self-expanding Evolut™ PRO and PRO + TAVR systems, annular ultrasonography in patients with symptomatic severe aortic stenosis. Interim data were presented virtually at the Cardiovascular Science and Interventions (SCAI) Conference 2021. Evaluation and achievement of target implant depth in an attempt to reduce interactions with the conduction system. Read: What is proA optimization. At 30 days, an excellent safety outcome was observed with no death or disabling stroke and a low rate of pacemaker placement (8.8%). In addition, the Evolut platform showed excellent hemodynamic (blood flow) performance with a low mean gradient (8.1 mm Hg) and a low rate of residual aortic regurgitation in the majority of subjects. no/trace (80.4%) and mild residual (19.6%) at discharge. Patients were also discharged quickly with an average hospital stay of one day. The Conduction Disorders Pathway evaluates the effectiveness and considerations of cardiac team for monitoring and managing patients with conduction disturbances who may be considered for pacemaker placement after TAVR. results,” said Kendra Grubb, MD, surgical director of the Center for Structural Valves and Hearts at Emory Healthcare in Atlanta, and co-principal investigator in the OPTIMIZE PRO study, who presented the data at the meeting. “Interim results from this study show improvements, such as lower rates of pacemaker placement and next day hospital discharge, and support the hypothesis that the peak overlap technique can improve care. take care of the patient.” Read more: Elements of 56 The OPTIMIZE PRO Study is being conducted at 46 study sites in the US and Canada and up to 15 sites in Europe. The primary endpoint included all-cause mortality or all-stroke mortality at 30 days with secondary endpoints being time to hospital discharge, percentage of patients with above-average aortic regurgitation, and percentage of patients with aortic regurgitation. pacemaker implantation rates for new-onset or worsening conduction disturbances at 30 days. The study will also evaluate re-hospitalization rates and time to discharge at 30 days and one year. “As a leader in transvaginal valve therapies, we are committed to helping transplant centers standardize and further refine their TAVR care pathways to improve patient outcomes.” Nina Goodheart, president of the Structured Cardiology & Aorta business division, is part of the Cardiology Portfolio at Medtronic. “In addition to helping us better understand the site-driven dynamics around conduction disturbances following TAVR, the study also allowed us to generate additional evidence around the Evolut system’s advanced sealing layer. PRO and PRO+ and its impact on paravalvular leaks.” Evolut TAVR. Platforms, consisting of Evolut™ R, Evolut™ PRO and Evolut PRO + TAVR System, are indicated for symptomatic patients with severe aortic stenosis in all risk categories (extreme, high, moderate and low) in the United States. The Evolut PRO and PRO+ valves have a tissue-coated outer layer that increases the contact surface area between the valve and the aortic ring to further improve valve sealing. and cardiac arrhythmias. The company strives to provide products and services that bring economic and clinical value to consumers and healthcare providers worldwide. solution companies – relieve pain, restore health and prolong life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving doctors, hospitals and patients in more than 150 countries. The company is focused on working with stakeholders around the world to take better care of health together. Read more: The ultimate guide to buying gold toned jewelry | Top questions about Q&AAny’s future direction are subject to risk and uncertainty as described in Medtronic’s periodic reports in filings with the Securities and Exchange Commission. Actual results may differ significantly from predicted results. View original content for media download: http://www.prnewswire.com/news-releases/procedure-osystem-techniques-and-care-pathways-from-the-optimize-pro-clinical-study-show -promising-early -out results-for-disease-implanted-with-the-medtronic-evolut-tavr-system-301278580.htmlSOURCE Medtronic plcRead more: What time does the cookie bin serve lunch
Last, Wallx.net sent you details about the topic “Press Release❤️️”.Hope with useful information that the article “Press Release” It will help readers to be more interested in “Press Release [ ❤️️❤️️ ]”.
Posts “Press Release” posted by on 2021-08-27 21:57:49. Thank you for reading the article at wallx.net
